Biotech Investors Bow Out After Approvals on Sales Hurdles

When Human Genome Sciences Inc.’s lupus drug, Benlysta, won regulatory approval in March as the first treatment for the disease in more than 50 years, the company estimated the product may be worth $2.5 billion a year.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.